An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Trial details
- Registry ID
- NCT07020819
- Drugs studied
- Tanruprubart
TrialRedline tracks 7 clinical trials sponsored by Annexon, Inc.: 3 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)NCT07020819 | Tanruprubart | Recruiting | 2027-05-31Estimated |
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)NCT06510816 | Sham Administration, Vonaprument | Active not recruiting | 2027-07-31Estimated |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré SyndromeNCT04701164 | ANX005 | Completed | 2024-04-20Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)NCT04569435 | ANX005 | Completed | 2024-01-10Actual |
| A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyNCT04656561 | ANX007, Sham comparator | Completed | 2023-03-28Actual |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04691570 | ANX005 | Completed | 2023-01-17Actual |
| An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's DiseaseNCT04514367 | ANX005 | Completed | 2022-08-29Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: GA lesion growth rate Description: Change in GA lesion area as assessed by fundus autofluorescence (FAF) Time frame: Baseline to Month 12. After: Measure: Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area Description: GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed). Time frame: Baseline to Month 12.
Before: 31 Dec 2026. After: 31 May 2027.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits Time frame: Baseline through Month 15. After: Measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits Time frame: Baseline through Month 15 Measure: Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits Time frame: Baseline through Month 24.
Before: 31 Oct 2026. After: 31 Jul 2027.
NCT04514367 · Annexon, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease Measure: Pharmacokinetics (PK) of ANX005 Measure: Pharmacodynamics (PD) effects of ANX005. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Measure: Actual Dose of ANX005 Administered on Day 1 Measure: Actual Dose of ANX005 Administered on Week 22 Measure: Area Under the Concentration Versus Time Curve From Time 0 to t (AUC0-t) of ANX005 at Day 1 Measure: CSF Free Complement Component 1q (C1q) at Day 1 Measure: Blood Free C1q at Day 1 Measure: Change From Baseline in Complement C4a in CSF at Week 24 Measure: Change From Baseline in Complement C4a in CSF at Week 36 Measure: Change From Baseline in CSF NfL Level at Week 24 Measure: Change From Baseline in CSF NfL Level at Week 36 Measure: Change From Baseline in Blood NfL Level at Week 24 Measure: Change From Baseline in Blood NfL Level at Week 36.
Before: 28 Jan 2022. After: 29 Aug 2022.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety: Treatment-emergent adverse events (TEAEs) Measure: Change in disease activity biomarkers. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Maximum Change From Baseline in Hemoglobin Levels Measure: Change From Baseline in Lactate Dehydrogenase Levels at Day 71 Measure: Change From Baseline in Percentage of Reticulocytes/Total Cells Count at Day 71 Measure: Change From Baseline in Haptoglobin Levels at Day 71 Measure: Change From Baseline in Total Bilirubin Levels at Day 71 Measure: Change From Baseline in Indirect Bilirubin Levels at Day 71.
Before: 6 participants (actual). After: 7 participants (actual).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of patients experiencing a best corrected visual acuity (BCVA) ≥15-letter loss from baseline through the primary timepoint as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at any two consecutive visits.. After: Measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits.
Before: Dec 2026. After: 31 Dec 2026.
Before: Not yet recruiting. After: Recruiting.